The markers Appl1, Sortilin, and Syndecan-1, which are at critical control points in the endosome-lysosome system, form a biomarker panel that can accurately map the pathogenesis in prostate cancer and assist Gleason grading to enable more accurate prediction of biochemical and clinical recurrence in patients [9, 11]. This evidence concerns the gene APPL1 and prostate carcinoma.